Single-dose pharmacokinetics of amprenavir coadministered with grapefruit juice

被引:13
作者
Demarles, D
Gillotin, C
Bonaventure-Paci, S
Vincent, I
Fosse, S
Taburet, AM
机构
[1] Lab Glaxo SmithKline, Marly Le Roi, France
[2] Hop Bicetre, Paris, France
关键词
D O I
10.1128/AAC.46.5.1589-1590.2002
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
In this crossover study in 12 healthy volunteers, coadministration of amprenavir (1,200 mg; single dose) with grapefruit juice slightly reduced the maximum concentration of drug in serum (C-max) compared to administration with water (7.11 versus 9.10 mug/ml), slightly increased the time to C-max (1.13 versus 0.75 h), and did not affect the area under the concentration-time curve from 0 to 12 h (AUC(0-12)), the AUC(0-infinity), or the concentration at 12 h. Therefore, grapefruit juice does not clinically significantly affect amprenavir pharmacokinetics.
引用
收藏
页码:1589 / 1590
页数:2
相关论文
共 6 条
[1]   Grapefruit juice-drug interactions [J].
Bailey, DG ;
Malcolm, J ;
Arnold, O ;
Spence, JD .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 46 (02) :101-110
[2]  
JAYEWARDENE A, 2001, J CHROMATOGR, V707, P203
[3]   USE OF NON-PARAMETRIC METHODS IN STATISTICAL-ANALYSIS OF 2-PERIOD CHANGE-OVER DESIGN [J].
KOCH, GG .
BIOMETRICS, 1972, 28 (02) :577-+
[4]   Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man [J].
Kupferschmidt, HHT ;
Fattinger, KE ;
Ha, HR ;
Follath, F ;
Krähenbühl, S .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 45 (04) :355-359
[5]   Safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus (HIV) type 1 protease inhibitor, following oral administration of single doses to HIV-infected adults [J].
Sadler, BM ;
Hanson, CD ;
Chittick, GE ;
Symonds, WT ;
Roskell, NS .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (07) :1686-1692
[6]   In vivo effect of α1-acid glycoprotein on pharmacokinetics of amprenavir, a human immunodeficiency virus protease inhibitor [J].
Sadler, BM ;
Gillotin, C ;
Lou, Y ;
Stein, DS .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (03) :852-856